Researchers from Wageningen Bioveterinary Research have joined the European Network of Vaccine Adjuvants (ENOVA), which brings together European experts and stakeholders working in different areas of adjuvant and vaccine research and development, including both prophylactic and therapeutic applications as well as human and veterinary vaccines.
ENOVA is funded by COST through the EU Framework Programme Horizon 2020 and is coordinated by the Vaccine Formulation Institute. The goals of the network are to facilitate communication and the exchange of information on adjuvants and vaccine formulation among its members, to ensure that new discoveries are widely disseminated so that their potential can be of optimal benefit, to promote the best use of existing adjuvant technologies, and to encourage and support the development of novel adjuvants and vaccines. Currently organizations from 28 countries joined ENOVA.
Vaccines are one of the most successful tools for prevention and control of infectious diseases in humans and animals. Despite success in the control of multiple infectious diseases, there are still many infectious diseases for which no effective vaccine is available. Adjuvants are substances that, when mixed with vaccine antigens, enhance the immune responses to the antigen, and they are subsequently an essential feature of modern vaccine development. While traditional prophylactic vaccines prevent disease, therapeutic vaccines are a promising novel strategy to treat and cure cancer, autoimmune diseases, and infectious diseases by stimulating the immune system to fight the disease. Adjuvants are an essential component in therapeutic vaccines in order to elicit an appropriate and effective immune response.
ENOVA is a COST Action. COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks and helps connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.